Clinical trial

Efficacy of ε-Aminocaproic Acid (EACA) in Children Undergoing Craniofacial Reconstruction Surgery

Name
PRO00004263
Description
The purpose of this study is to determine whether Amicar (ε-aminocaproic acid) is effective in reducing blood loss in children undergoing craniofacial reconstruction surgery. The investigators hypothesize that Amicar will decrease intraoperative blood loss and decrease the need for perioperative blood product administration in children undergoing craniofacial surgery.
Trial arms
Trial start
2014-10-01
Estimated PCD
2025-01-01
Trial end
2025-03-01
Status
Active (not recruiting)
Phase
Early phase I
Treatment
Amicar (ε-aminocaproic acid)
Arms:
Amicar (ε-aminocaproic acid)
Other names:
Amicar, 6-aminohexanoic acid, epsilon aminocaproic acid
normal saline
Arms:
normal saline
Other names:
normal saline 0.9%, placebo, placebo control
Size
22
Primary endpoint
Intraoperative blood loss
within the first 72 hours after surgery
Eligibility criteria
Inclusion Criteria: * Any child diagnosed with craniosynostosis in need of surgical repair * Males and females between the ages of 2 - 36 months (minorities will be included) * Surgical procedure involving complex craniofacial reconstruction and craniotomy * Written informed consent from parent/guardian Exclusion Criteria: * Subjects with known or suspected hypersensitivity reaction to Amicar or history of prior Amicar exposure * Presence or prior history of a known coagulation disorder or hypercoagulable state * Preoperative laboratory values that indicate clinically significant hematologic disease (hemoglobin, platelet count, prothrombin time, or partial thromboplastin time outside of normal range) * Subjects who are on anticoagulant therapy (Coumadin, heparin, aspirin, etc.) * Subjects with a prior history of a thrombotic event * History of renal malformation * Presence of hematuria * History of abnormal renal function - serum creatinine or blood urea nitrogen (BUN) value greater than 1.5 times the upper limit of the normal range * Craniofacial reconstruction surgery performed in conjunction with an additional surgical procedure associated with blood loss * Subjects who have been previously enrolled in this protocol may not be enrolled again
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 22, 'type': 'ACTUAL'}}
Updated at
2023-09-01

1 organization

1 product

1 indication

Product
Amicar